Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function

Fig. 5

TIGIT-28 enhances the function of anti-CD19-BBz CAR-T cells. a primary T-cells engineered to express the a CD19-specific CAR were co-transduced with TIGIT-28 or a control gene (tr. CD34) and analyzed for CAR expression by flow cytometry using protein-L staining. b Different target cells were transduced with a retroviral vector encoding CD155. CD155 expression in the native (WT) or the CD155-engineered (CD155 tr.) target cell lines was assessed by flow cytometry. The percentage of positive cells (indicated by the grey surface) and the MFI (in brackets) are shown. These results are representative of 6 independent experiments. c-e Human T-cells were engineered to express a 2nd generation (41BB-based) CD19-specific CAR and co-transduced with TIGIT-28 or a control gene (tr. CD34). These cells were co-cultured with CD155 negative target cells (c), native CD155 positive target cells (d), and CD155-transduced target cells (e). TNFα secreted in the co-culture supernatant was measured by ELISA. Cytokine concentrations were normalized for each target cell line (with or w/o CD155) to the secretion observed in the positive control Ctrl/CD19-BBz group with an average TNFα secretion of 5884 pg/ml for Raji, 4558 pg/ml for JY, 4330 pg/ml for 721.221, 8102 pg/ml for K562-CD19 and 3902 pg/ml for Nalm6. These results represent the mean + SEM of at least 6 independent experiments, performed with 6 different donors (*: p < 0.05, calculated using a Student’s paired t-test)

Back to article page